Celltrion is rapidly increasing its market share in Asia and Latin America, establishing a new growth engine following the United States and Europe.
On October 20, Celltrion announced that its autoimmune disease treatment, Remsima (ingredient name infliximab), achieved a 48% market share in Japan's infliximab prescription market in July, surpassing the original drug Remicade to take the top spot. Remsima is a biosimilar of Remicade, used for treating rheumatoid arthritis and Crohn's disease.
In Japan, the cancer drugs Herceptin (trastuzumab) and Avastin (bevacizumab) also recorded market shares of 78% and 64%, respectively. As of the first quarter of this year, Remsima held the number one position in Singapore (93%), Hong Kong (84%), Thailand (78%), and Malaysia (72%).
The company is also expanding its presence in the Latin American market. In Brazil's private market, Remsima has captured approximately 60% market share, while in Costa Rica, Remsima and the blood cancer treatment Truxima have nearly 100% market share. In Ecuador, the Dominican Republic, and Paraguay, key product shares have exceeded 80%.
As of the third quarter, Celltrion operates subsidiaries in 43 countries worldwide, with 13 located in growth markets such as Asia and Latin America. The workforce in Japan has increased to over 80 employees, with about 25% of overseas staff working in Asia and Latin America.
The company plans to introduce additional products to its established sales network. Recently, it launched the intravenous formulation of the autoimmune disease treatment Stelara (ustekinumab) in Japan and plans to release the subcutaneous formulation of Remsima SC in 2027. In Thailand, it is working on the launch of the allergy treatment Omnipaque (omalizumab) and the osteoporosis treatment Denosumab (Prolia).
A Celltrion representative stated, "The fact that Remsima has surpassed the original drug to become number one in Japan indicates that our product competitiveness and global sales strategy are yielding results. We will expedite the launch of new products in Asia and Latin America to diversify our growth engines."
Meanwhile, Celltrion reported on October 12 that its consolidated revenue for the third quarter reached 1.5 trillion won, with an operating profit of 510 billion won. This represents a 45.8% increase in revenue and a 69.2% increase in operating profit compared to the same period last year, marking the highest quarterly figures to date. Cumulative revenue for the first three quarters stands at 4.0387 trillion won. The company aims for annual revenue of 5.3 trillion won and an operating profit of over 600 billion won in the fourth quarter.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.